Advertisement

TheBodyPRO.com Covers CROI 2017

News

Safety Important in Pre-Exposure Prophylaxis Trials

March 4, 2017

If there is compelling evidence that [a certain agent] works, we stop the trial straight away and let the world know what's going on.

-- Deborah Donnell, Ph.D.

In an interview on behalf of IFARA at CROI 2017, Fred Schaich spoke with researchers about pre-exposure prophylaxis (PrEP). That HIV prevention method is now included in most discussions on preventing transmission of the virus.

Researchers are working on various agents that could be used orally or topically, including long-acting injectables, monoclonal antibodies and implants. There is no evidence yet that monoclonal antibodies work to prevent HIV in humans. However, clinical trials include safety precautions, including a mechanism for stopping a study if the study drug proves effective so that those in the study's placebo arm can also benefit from it.

The rates of sexually transmitted infections (STIs) have increased with the wider use of oral HIV prevention methods. New strategies for reducing STI rates are therefore needed and can be informed by HIV prevention studies. Another concern is the interaction between contraceptives and HIV prevention agents. One solution might be to pair a contraceptive and a PrEP agent.

Watch the video to learn more:



About the panelists:

  • Myron S. Cohen, M.D., University of North Carolina-Chapel Hill, N.C. and HIV Prevention Trials Network.
  • Deborah Donnell, Ph.D., University of Washington, Seattle, and Fred Hutchinson Cancer Research Center.
  • Jared Baeten, M.D., Ph.D., Department of Global Health, University of Washington, Seattle.
  • Jean-Michel Molina, M.D., Ph.D., Department of Infectious Diseases, Saint-Louis Hospital, Paris, France.

The video above has been posted on TheBodyPRO.com with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.

Barbara Jungwirth is a freelance writer and translator based in New York.

Follow Barbara on Twitter: @reliabletran.


Related Stories

HIV Transmission Despite Adherence to PrEP and No Drug Resistance
New HIV Infections Drop 18% in 6 Years



This article was provided by TheBodyPRO.com. It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.